PMC5066989_01
Fluorescence in situ immuno-hybridization signals of ALK.. Note: Split red and green signals indicate broken-apart ALK gene.
ott-9-6059Fig1.jpg
PMC5066989_01_ott-9-6059Fig1.jpg
f1-ott-9-6059
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital (Figure 1).
Magnetic resonance imaging scans depicting the response of intracranial metastases and change in meningeal thickness after crizotinib rechallenge treatment.. Notes: (A, B) Cerebral metastatic foci and meningeal thickness, and (D, E) positive response to the second administration of crizotinib after 1 week. (C, F) Progression of hepatic metastasis. Arrow indicates brain metastasis, and the arrowhead indicates leptomeningeal metastasis.
ott-9-6059Fig2.jpg
PMC5066989_01_ott-9-6059Fig2.jpg
f2-ott-9-6059
Laboratory data demonstrated no significant abnormality, while the multiple enhanced lesions appeared with meningeal thickening (Figure 2A and B). One week after the commencement of crizotinib treatment, magnetic resonance imaging revealed shrinkage of metastatic foci and peritumoral edema in the brain (Figure 2D) and meningeal thickening (Figure 2E). However, hepatic metastasis had progressed (Figure 2C and F) and the patients' nausea and poor performance status were not greatly improved.